Acrivon Therapeutics (ACRV) Change in Account Payables (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Change in Account Payables of -$1.2 million for Q1 2026, down 142.68% year-over-year from $2.8 million in Q1 2025, and down 193.83% quarter-over-quarter from $1.3 million in Q4 2025.
Acrivon Therapeutics (ACRV) Change in Account Payables (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Change in Account Payables for 6 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 142.68% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$2.5 million (down 265.25% YoY), while the FY2025 annual figure was $1.5 million, up 142.83% from the prior year.
- Change in Account Payables retreated to -$1.2 million in Q1 2026 per ACRV's latest filing, from $1.3 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.2 million in Q4 2023 and bottomed at -$2.6 million in Q2 2025.
- Historically, Change in Account Payables has averaged $6588.2 across 5 years, with a median of -$95000.0 in 2022.
- Annual changes were most pronounced in 2024 — Change in Account Payables slumped 781.31% — and 2025, when it jumped 654.55%.
- Acrivon Therapeutics' Change in Account Payables stood at -$727000.0 in 2022, then soared by 536.04% to $3.2 million in 2023, then slumped by 107.29% to -$231000.0 in 2024, then jumped by 654.55% to $1.3 million in 2025, then plunged by 193.83% to -$1.2 million in 2026.
- Business Quant data shows ACRV's Change in Account Payables at -$1.2 million in Q1 2026, $1.3 million in Q4 2025, and -$9000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | -214,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -214,000.00 |
| Jun 30, 2026 | -214,000.00 |
| Mar 31, 2026 | -1.20 Mn |
| Mar 31, 2026 | -1.20 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | -9,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Jun 30, 2025 | -2.55 Mn |
| Jun 30, 2025 | -2.55 Mn |
| Mar 31, 2025 | 2.82 Mn |
| Mar 31, 2025 | 2.82 Mn |
| Dec 31, 2024 | -231,000.00 |
| Dec 31, 2024 | -231,000.00 |
| Sep 30, 2024 | -140,000.00 |
| Sep 30, 2024 | -140,000.00 |
| Jun 30, 2024 | -943,000.00 |
| Jun 30, 2024 | -943,000.00 |
| Mar 31, 2024 | -2.27 Mn |
| Mar 31, 2024 | -2.27 Mn |